Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 December;59(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 December;59(4):439-45

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 December;59(4):439-45

DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF LOCALLY ADVANCED AND ADVANCED PROSTATE CANCER 

    REVIEWS

Prostate cancer as a chronic disease: cost-effectiveness and proper follow-up

Guttilla A. 1, Bortolami A. 2, Evangelista L. 3

1 Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Padua, Italy;
2 Oncology Unit 2, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy;
3 Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy

In western countries, prostate cancer (PCa) is the most common non-dermatological malignant disease in men. Bone metastases more often develop in patients with advanced PCa; the associated complications present a substantial disease and economic burden. Although the introduction of new therapeutic strategies have provided some advantages in terms of overall survival and quality of life in patients with metastatic PCa, the skeletal related events and side effects due to the therapies are associated with an important impact on the healthcare costs. In particular, the number of hospital admission, clinical consultation and the introduction of new expensive diagnostic modalities have changed the management of metastatic patients. However, the National and International guidelines suggest to follow patients with metastatic PCa by using clinical assessment, biochemical evaluation and, when necessary, diagnostic imaging. The aims of the present review were: 1) to summarize the information regarding the clinical and economic burden of metastasis; 2) to evaluate the quality of life; and 3) to suggest a proper follow-up in advanced PCa patients.

language: English


FULL TEXT  REPRINTS

top of page